Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas Buckner Johnson, Justin Micah Balko, Margaret Compton et al. · New England Journal of Medicine · 2016
Summ a r yImmune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy.We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab.In both patients, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with a robust presence of T-cell and macrophage infiltrates.Selective clonal T-cell populations infiltrating the myocardium were identical to those present in tumors and skeletal muscle.Pharmacovigilance studies show that myocarditis occurred in 0.27% of patients treated with a combination of ipilimumab and nivolumab, which suggests that our patients were having a rare, potentially fatal, T-cell-driven drug reaction.(Funded by Vanderbilt-Ingram Cancer Center Ambassadors and others.)I mmune checkpoint inhibitors have transformed the treatment of several cancers by releasing restrained antitumor immune responses.1 Ipilimumab, an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody, and nivolumab, an anti-programmed death-1 (PD-1) antibody, have individually improved survival in patients with melanoma, and early results suggest that their combination further enhances antitumor activity and survival.[2][3][4][5] Other adverse events associated with these agents include dermatitis, endocrinopathies, colitis, hepatitis, and pneumonitis, which are all thought to arise from aberrant activation of autoreactive T cells.6,7 These toxic effects are more frequent and severe when ipilimumab and nivolumab are used in combination.4 Here, we report two cases of lethal myocarditis accompanied by myositis in patients treated with a combination of nivolumab and ipilimumab.
Cited by 2,288 works. doi:10.1056/nejmoa1609214 Open-access PDF
Authors
- Douglas Buckner Johnson
- Justin Micah Balko
- Margaret Compton
- Spyridon G. Chalkias
- Joshua Gorham
- Yaomin Xu
- Mellissa J. Hicks
- Igor J. Puzanov
- Matthew R. Alexander
- Tyler L. Bloomer
- Jason R. Becker
- David Slosky
- Elizabeth Jane Phillips
- Mark A. Pilkinton
- Laura D. Craig-Owens
- Nina Kola
- Gregory E. Plautz
- Daniel S. Reshef
- Jonathan S. Deutsch
- Raquel P. Deering
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma